Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 247

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Open access
Subbiah, Vivek, Cassier, Philippe A., Siena, Salvatore, Garralda, Elena, Paz-Ares, Luis, Garrido, Pilar, Nadal, Ernest, Vuky, Jacqueline, Lopes, Gilberto, Kalemkerian, Gregory P., Bowles, Daniel W., Seetharam, Mahesh, Chang, Jianhua, Zhang, Hui, Green, Jennifer, Zalutskaya, Alena, Schuler, Martin, Fan, Yun, Curigliano, Giuseppe · 2022 · Nature Medicine

Abstract

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered solid tumors. Twenty-nine patients with 12 different RET fusion–positive solid tumor types, excluding non-small-cell lung cancer and thyroid cancer, who had previously received or were not candidates for standard therapies, were enrolled. The most common RET fusion partners in 23 efficacy-evaluable patients were CCDC6 (26%), KIF5B (26%) and NCOA4 (13%). Overall response rate, the primary endpoint, was 57% (95% confidence interval, 35–77) among these patients. Responses were observed regardless of tumor type or RET fusion partner. Median duration of response, progression-free survival and overall survival were 12 months, 7 months and 14 months, respectively. The most common grade ≥3 treatment-related adverse events were neutropenia (31%) and anemia (14%). These data validate RET as a tissue-agnostic target with sensitivity to RET inhibition, indicating pralsetinib’s potential as a well-tolerated treatment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusion–positive solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01931-y

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 247

Metadata

Authors
Subbiah, V., Cassier, P. A., Siena, S., Garralda, E., Paz-Ares, L., Garrido, P., Nadal, E., Vuky, J., Lopes, G., Kalemkerian, G. P., Bowles, D. W., Seetharam, M., Chang, J., Zhang, H., Green, J., Zalutskaya, A., Schuler, M., Fan, Y., & Curigliano, G.
Venue
Nature Medicine
Published
2022-08
Volume
28
Issue
8
Pages
1640-1645
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4290860519
Cited by
247
References
8
FWCI
29.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial. https://app.cochat.ai/papers/10.1038/s41591-022-01931-y
The paper
Subbiah, V., Cassier, P. A., Siena, S., Garralda, E., Paz-Ares, L., Garrido, P., Nadal, E., Vuky, J., Lopes, G., Kalemkerian, G. P., Bowles, D. W., Seetharam, M., Chang, J., Zhang, H., Green, J., Zalutskaya, A., Schuler, M., Fan, Y., & Curigliano, G. (2022). Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01931-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.